检索结果-南通市图书馆

A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study

引用

Health 2013年第7期5卷 30-40页

作者： Yesim Gokce Kutsal Nurten Eskiyurt Jale Irdesel Vesile Sepici Hatice Ugurlu Yesim Kirazli Fusun Ardic Mirko Korsic Tonko Vlak Mane Grlickov Snezana Markovic Temelkova Miroslav Lazarov Nada Pilipovic Vera Popovic Aleksandar Dimic Branka Kovacev Dorina Ruci Argjend Tafaj Elma Kucukalic-Selimovic Dijana Avdic Hajrija Seleskovic Snjezana Pejicic Bulent Butun Gulseren Akyuz Lale Cerrahoglu Omer Faruk Sendur Peyman Yalcin Sema Oncel Merih Saridogan Tunay Sarpel Mehmet Tosun Kazim Senel Savas Gursoy ferhan canturk Huseyin Demir Blazenka Miskic Dalibor Krpan Franjo Skreb Simeon Grazio Zeljka Crncevic-Orlic Fatih Ozdener Hakan Oncel Clinic for Orthopaedic Surgery Clinical Centre Vodnjansk Skopje Macedonia Clinic of Endocrinology Diabetes and Metabolic Disorders Skopje Macedonia Clinic of Rheumatology Clinical Centre Skopje Macedonia Clinical Center of Vojvodina Novi Sad Serbia Clinical Center Banja Luka Bosnia and Herzegovina Clinical Hospital Centre Split Croatia Department of PMR Cerrahpasa School of Medicine Istanbul University Istanbul Turkey Department of PMR Clinical Hospital Center Rijeka Rijeka Croatia Department of PMR Dr. Josip Bencevic General Hospital Slavonski Brod Croatia Department of PMR Istanbul School of Medicine Istanbul University Istanbul Turkey Department of PMR Polyclinic for Internal Medicine Zagreb Croatia Department of PMR School of Medicine Adnan Menderes University Aydin Turkey Department of PMR School of Medicine Akdeniz University Ankara Turkey Department of PMR School of Medicine Ankara University Ankara Turkey Department of PMR School of Medicine Ataturk University Erzurum Turkey Department of PMR School of Medicine Celal Bayar University Manisa Turkey Department of PMR School of Medicine Cukurova University Adana Turkey Department of PMR School of Medicine Dokuz Eylul University Izmir Turkey Department of PMR School of Medicine Ege University Izmir Turkey Department of PMR School of Medicine Erciyes University Kayseri Turkey Department of PMR School of Medicine Gazi University Ankara Turkey Department of PMR School of Medicine Gaziantep University Gaziantep Turkey Department of PMR School of Medicine Hacettepe University Ankara Turkey Department of PMR School of Medicine Karadeniz Technical University Trabzon Turkey Department of PMR School of Medicine Marmara University Istanbul Turkey Department of PMR School of Medicine Ondokuz Mayis University Samsun Turkey Department of PMR School of Medicine Pamukkale University Denizli Turkey Department of PMR School of Medicine Selcuk University Konya Turkey Department

A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to-treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment.

关键词： Bisphosphonate Compliance Ibandronate Postmenopausal Osteoporosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：